Bronax Flex

Quick links to important sections

Bronax Flex

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bronax Flex

Quick Facts

Property Description
Active Ingredient Meloxicam, Pridinol
Form Tablet or Capsule (Oral)
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID) and Centrally Acting Muscle Relaxant
Common Use Relief of pain associated with muscle stiffness and inflammation
Origin Synthetic

Defining Bronax Flex: Type and Identity

Bronax Flex is defined as a Fixed-Dose Combination (FDC) product designed for oral administration, typically supplied as a tablet or capsule. This medication is a synthetic preparation that integrates two distinct active pharmaceutical ingredients (Meloxicam and Pridinol) into a single unit. This formulation is clinically recognized for its streamlined approach to managing complex pain conditions, often eliminating the need for patients to manage two separate prescriptions. The FDC design ensures the synchronized delivery of both components, allowing for a comprehensive therapeutic strategy against musculoskeletal symptoms.

What Pharmacological Classes are Combined in Bronax Flex?

The composition unites a Nonsteroidal Anti-inflammatory Drug (NSAID) with a Centrally Acting Muscle Relaxant. Meloxicam is an NSAID belonging to the oxicam derivative class, known for its mechanism as a preferential cyclooxygenase-2 (COX-2) inhibitor. This component primarily addresses the inflammatory process. Simultaneously, Pridinol acts as a Centrally Acting Muscle Relaxant, modulating central nerve activity to reduce excessive muscle stiffness. This combination is intended for the management of pain where both inflammation and muscle tension are contributing factors.

General Purpose of the Dual-Action Formulation

The general therapeutic purpose of Bronax Flex is to comprehensively address acute discomfort that stems from both inflammatory processes and associated muscle contracture, such as severe lower back pain or muscle spasms following injury. The dual-action formulation leverages the anti-inflammatory and analgesic activity of the NSAID component and the tension-releasing effect of the muscle relaxant. This strategy aims to resolve both the underlying irritation and the involuntary muscle tightness, ultimately supporting improved comfort and functional mobility.

What side effects are possible with Bronax Flex?

Possible Side Effects and Safety Information

The official safety profile for Bronax Flex, a combination of an NSAID (Meloxicam) and a muscle relaxant (Pridinol), is based on the adverse reactions and risk classifications documented in government regulatory sources, such as FDA labeling and European SmPCs. This profile details adverse reactions grouped by frequency and the body systems they affect.

Documented Adverse Reactions

The most frequently documented reactions often involve the Gastrointestinal Disorders (e.g., nausea, abdominal pain, diarrhea, dyspepsia) and the Nervous System Disorders (e.g., headache, dizziness, drowsiness). These effects are classified as Common or Uncommon according to regulatory standards.

Serious Adverse Reactions and Risk Patterns

The regulatory documentation highlights the potential for serious, life-threatening events associated with the NSAID component. These include the risk of Serious Cardiovascular Thrombotic Events (such as myocardial infarction and stroke) and Serious Gastrointestinal Events (bleeding, ulceration, and perforation).

Risk patterns tied to use are officially stated: the risk of serious cardiovascular events may increase with the duration of use, and severe cutaneous reactions may be more likely within the first weeks of treatment initiation.

Safety Constraints and Special Populations

Official labeling defines specific safety constraints. The medication is generally restricted (contraindicated) in individuals with a known history of hypersensitivity to NSAIDs, active gastrointestinal bleeding, or severely impaired organ function (hepatic, renal, or uncontrolled heart failure). Additionally, regulatory documents note that older adults are at a higher risk for serious gastrointestinal and cardiovascular adverse events, requiring explicit safety consideration.

Overdose and Emergency Response

Overdose: When to Seek Help

Official regulatory information for products related to Bronax Flex emphasizes that an overdose can lead to serious, life-threatening outcomes. The principal concern is severe central nervous system (CNS) depression, which affects the body’s ability to breathe.

Documented Overdose Symptoms

The clinical manifestations of an overdose, as described in regulatory documents for these drug classes, include:

  • Extreme sleepiness
  • Slowed or difficult breathing (respiratory depression)
  • Coma and unresponsiveness
  • Death

High-Risk Factors

Overdose risk is significantly increased by two factors: exceeding the recommended dosage or duration of use, and the combined use of this medicine with other Central Nervous System depressants. These depressants include benzodiazepines, other prescription medicines that cause drowsiness, and alcohol. This combination greatly magnifies the risk of severe respiratory problems.

Required Emergency Action

Immediate medical attention is required if any of the severe overdose symptoms are observed, such as extreme drowsiness, slowed breathing, or unresponsiveness. Do not wait for symptoms to worsen; contact emergency medical services or a poison control center right away. The regulatory imperative is to seek help before serious complications with breathing occur. Patients with certain underlying conditions, such as severe asthma, should also seek prompt medical review if their condition worsens despite use.

Therapeutic Uses of Bronax Flex

What Bronax Flex Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed for acute episodes of musculoskeletal discomfort. The NSAID component is commonly used to ease pain, tenderness, swelling, and stiffness associated with inflammatory conditions. The combination is applied across domains where additional symptomatic support is needed when symptoms related to inflammatory or irritative states and symptoms of increased muscular activity present simultaneously.

The medication is commonly used to help with conditions characterized by periods of heightened symptoms such as acute low back pain (lumbago), stiff neck, and general musculoskeletal pain involving contractures. It is applied in addressing symptoms that interfere with daily functioning, particularly during phases of sudden discomfort or functional strain. The symptomatic relief offered contributes to improved comfort during periods of heightened symptoms and provides supportive relief when symptoms interfere with routine activities.


Quick Fact Block

Quick Fact: Musculoskeletal Symptom Management Description
Primary Target Symptoms Pain, localized inflammation, and painful muscle contractures.
Typical Context Acute episodes of musculoskeletal discomfort and related functional strain.
Therapeutic Benefit Supports symptom management and contributes to improved day-to-day comfort.

Regulatory References

  1. NIH MedlinePlus overview of Meloxicam

Eligibility and Restrictions for Use

Who can and cannot use Bronax Flex? — Official Eligibility Information

Bronax Flex (which contains Meloxicam, a Non-Steroidal Anti-inflammatory Drug or NSAID) is not appropriate for all patients and has several formal restrictions and contraindications defined in regulatory documents.

Contraindicated Populations

Use is strictly contraindicated for individuals with:

  • A known allergy or hypersensitivity to meloxicam or any ingredient in the product.
  • A history of asthma, hives, or other allergic-type reactions after taking aspirin or other NSAIDs.
  • Treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
  • An active peptic ulcer or existing gastrointestinal bleeding.

Restricted or Special Consideration Groups

Certain groups require special caution or have explicit restrictions on use:

  • Pregnancy: Avoid use from about 30 weeks gestation and later due to the risk of fetal harm. Use between 20 to 30 weeks should be limited and managed by a healthcare provider.
  • Pediatric Use: The product is indicated for Juvenile Rheumatoid Arthritis in patients 2 years of age and older.
  • Renal/Hepatic Impairment: Avoid use in patients with advanced renal disease or severe hepatic impairment unless benefits outweigh risks. Use in severe renal impairment is not recommended.
  • Cardiovascular Conditions: Use should be avoided in patients with severe heart failure.
  • Older Adults: Patients aged 65 years and older are at a greater risk for serious gastrointestinal and cardiovascular events, requiring cautious monitoring.

What should I know about interactions with other medicines?

The interaction profile for Bronax Flex is defined by the official regulatory information for its two active components, Meloxicam and Pridinol. This section details officially documented constraints for co-administration of other medicinal products, substances, or conditions.

Interaction Category Documented Constraint and Outcome
Formal Contraindications Other NSAIDs (including analgesic Aspirin) are strictly contraindicated due to the risk of severe gastrointestinal adverse events. Use is also restricted in the setting of peri-operative pain for CABG surgery (Coronary Artery Bypass Graft).
Pharmacodynamic Risks Co-administration with Oral Anticoagulants (e.g., Warfarin) increases the documented risk of bleeding complications. Antihypertensive medicines (ACE Inhibitors, ARBs, Diuretics) may have their blood pressure-lowering effects diminished. Pridinol may formally reinforce the effects of other anticholinergic medicines.
Exposure Modification Concomitant use with Lithium or Methotrexate raises their respective plasma concentrations to potentially toxic levels due to reduced clearance. Cyclosporine and Tacrolimus carry an increased regulatory risk of nephrotoxicity. Cholestyramine accelerates the elimination of Meloxicam, resulting in reduced exposure.
Substance and Population Notes The combination with Alcohol may increase the documented risk of serious gastrointestinal bleeding. Elderly, volume-depleted, or renal-impaired patients face a heightened risk of acute renal function deterioration when co-administered with ACE Inhibitors or ARBs.

Mechanism of Action

Blocking Inflammatory Signaling via COX-2 Inhibition

The Meloxicam component acts as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme, the primary molecular target responsible for generating pro-inflammatory mediators, such as PGE2. By suppressing this enzyme, the drug interrupts the arachidonic acid cascade, leading to a physiological decrease in inflammatory mediator concentration and reduced excitability of peripheral nociceptors.


Central Modulation of Skeletal Muscle Tone

The Pridinol component exerts its function as a centrally-acting muscle relaxant by antagonizing muscarinic acetylcholine receptors ( mAChR), particularly those in the spinal cord. This mechanism decreases the excitability of spinal motor neurons, thereby modulating the intensity of polysynaptic reflex activity, which governs the level of pathological muscle hypertonia.


Dual-Pathway Mechanistic Synergy

The combined physiological modulation of Bronax Flex involves the engagement of two distinct systems: the peripheral inflammatory cascade and the central neuro-motor system. This coordination allows for simultaneous modulation of the peripheral inflammatory cascade and the central neuro-motor pathways, resulting in an integrated physiological adjustment across both systems.

Dosage and Administration Information

How to Use Bronax Flex

The usage of Bronax Flex, a fixed-dose combination product containing an NSAID (Meloxicam) and a muscle relaxant (Pridinol), is governed by specific guidelines defining its administration and dosing patterns.

Administration Guidelines

Bronax Flex is approved for oral administration as a tablet or capsule. The standard regimen for the NSAID component establishes a starting dosage, typically 7.5 mg, which is taken once daily. The administration is generally intended as a single dose with water or other liquid and is often specified to be taken during a meal.

Instruction Entity Guideline
Route of Administration Oral
Dosing Frequency Once daily (qDay)
Maximum Adult Dose The NSAID component must not exceed 15 mg per day.

Dosing Principles and Special Populations

General principles emphasize administering the lowest effective dosage for the shortest duration possible that aligns with the symptomatic relief being managed. If a dose is missed, it should not be supplemented with a double dose. The medication is to be taken at the next scheduled time.

For certain patient groups, specific dosage limits apply to the NSAID component. For older adults starting long-term treatment, the initial amount is recommended to be 7.5 mg per day. Furthermore, patients with severe renal impairment (e.g., those undergoing hemodialysis) must have their dosage restricted to a maximum of 7.5 mg per day. These standards ensure that the administration of Bronax Flex follows the dosage and frequency constraints defined for the product.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Early-Stage Research

Studies have explored whether the compound may influence joint inflammation and associated pain. Research has investigated the theoretical basis for how the compound might work. Some studies have investigated the absorption profile of the compound, with varied findings.


Clinical Trials: Efficacy and Outcomes

Research in early-stage clinical trials has focused on whether the compound is associated with changes in symptoms related to chronic joint discomfort.

  • Pain and Mobility: Research has examined whether the compound might be associated with changes in patient mobility and joint function over a 4-week period. Findings are mixed regarding whether this combination of ingredients might influence the sensation of chronic discomfort.
  • Flare-ups: Research has not yet established a recommended timing for administration, nor whether administration may influence the frequency of flare-ups. A long-term study evaluated whether the compound might be associated with changes in quality of life metrics.
  • Comparative Trials: Comparative trials are limited, though some studies have examined the compound in relation to other available treatments.

Safety and Patient Considerations

The frequency of adverse events was tracked in the studied populations. The most commonly reported events have included mild gastrointestinal upset and temporary fatigue.

Safety studies are ongoing, and research regarding individuals with pre-existing conditions, such as kidney impairment, is still developing. It is not yet clear whether the compound may interact with other medications; research on potential drug-drug interactions remains limited.

Frequently Asked Questions (FAQ)

Common questions about Bronax Flex (FAQ)


Q: How quickly does Bronax Flex start working?

A: Regulatory documents indicate that the time to reach the highest concentration of the NSAID component in the blood is typically achieved a few hours after administration. This timeline helps describe the general time frame in which the component reaches its peak measurable levels.


Q: How is Bronax Flex different from other similar medicines?

A: Bronax Flex is defined in official information as a Fixed-Dose Combination (FDC) product. This means it uniquely combines two distinct active ingredients—a Nonsteroidal Anti-inflammatory Drug (NSAID) and a Centrally Acting Muscle Relaxant—into a single pill. This dual composition is its primary difference from single-ingredient medicines.


Q: Is Bronax Flex addictive?

A: According to official regulatory classifications, the active components of the drug are non-controlled substances. This classification informs the assessment of potential for dependence or misuse.


Q: Does Bronax Flex cause weight gain?

A: Official safety documents indicate that a change in weight, including an increase or decrease, has been among the documented adverse events. This change in weight is sometimes noted as a symptom accompanying fluid retention.


Q: Is it common to feel tired while taking Bronax Flex?

A: Yes, official documents classify fatigue or tiredness as a documented adverse event. The most frequently reported events in clinical trials often include effects like headache, dizziness, and drowsiness.


Q: Is it okay to use Bronax Flex if I have kidney issues?

A: Official regulatory information strongly cautions against use in patients with advanced renal disease or severe renal impairment. For individuals with other kidney issues, official documents describe special considerations, including dosage restrictions for the NSAID component.


Q: Does Bronax Flex cause dryness or constipation?

A: Official safety documents include dry mouth and constipation among the documented side effects of the drug’s components. These effects are typically classified as less common adverse events.


Q: Can Bronax Flex affect my sleep?

A: Regulatory documents for the drug’s components list several side effects that may relate to sleep disturbance. These include insomnia (difficulty falling or staying asleep), abnormal dreaming, and general drowsiness.


Q: Are there any foods I should avoid when taking Bronax Flex?

A: Official information focuses on taking the drug with food. Regulatory documents also note that the combination with alcohol may increase the documented risk of serious gastrointestinal bleeding.


Q: Can I take Bronax Flex with vitamins or supplements?

A: Official interaction documents often advise caution or monitoring when the drug is used with certain supplements. For example, warnings are given for the potential of increased bleeding risk with herbs like ginkgo and the possibility of elevated potassium levels with potassium supplements.


Q: Is there a generic version of Bronax Flex available?

A: Official regulatory processes recognize generic versions of the NSAID component, Meloxicam. The availability of a generic version of the specific combination product is subject to regulatory approval and commercial status in each region where it is sold.


Q: Can Bronax Flex affect mood or mental clarity?

A: Regulatory documents for the components include reports of side effects that may affect mood or mental state. These documented effects include confusion, anxiety, irritability, and instances of mild depression.


Q: Does Bronax Flex need to be kept in the refrigerator?

A: Official instructions specify that the product should be stored at controlled room temperature, typically 20^circC to 25^circC (68^circF to 77^circF). The product must not be frozen and should be kept protected from moisture and high humidity.


Q: What should I do with expired Bronax Flex?

A: Official regulatory documents state that unused or expired medicine must not be disposed of via wastewater or routine household waste. Disposal should follow local requirements, which often involve organized programs for returning drugs.


Q: Does Bronax Flex work better with food or on an empty stomach?

A: Official guidelines often specify taking the drug with a meal. This practice is typically recommended to minimize the potential for gastrointestinal upset, a common adverse event associated with the NSAID component.


Q: Are there any restrictions on driving while taking Bronax Flex?

A: Official safety warnings describe the possibility of dizziness, drowsiness, or blurred vision. These warnings indicate that activities requiring mental alertness, such as driving or operating machinery, should be approached with caution.


Q: Has Bronax Flex been recalled or is it currently under safety review?

A: The regulatory history of the active NSAID component, Meloxicam, indicates it has been determined not to have been withdrawn from sale for reasons of safety or effectiveness. Official agencies maintain public databases for ongoing safety and recall information.


Q: Are there different strengths of Bronax Flex available?

A: The drug is commercially available in different strengths, which are defined by the precise amount of each active component. Regulatory bodies approve strengths such as the 15, mg (NSAID component) / 4, mg (muscle relaxant component).


Q: How does the mechanism of Bronax Flex relate to inflammation?

A: The mechanism of the NSAID component is to act as a preferential inhibitor of the Cyclooxygenase-2 (COX-2) enzyme. By suppressing this enzyme, the drug interrupts the production of pro-inflammatory mediators, which helps in reducing inflammation.

How should Bronax Flex be stored and disposed of?

The safe storage and disposal of Bronax Flex (Meloxicam/Pridinol) are strictly governed by regulatory labeling to maintain the drug’s stability and prevent accidental exposure.

Item Official Regulatory Statement
Storage Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Environmental Control The product must not be frozen and must be protected from moisture and high humidity.
Packaging Rules Keep the medicine in its original container and ensure the container is tightly closed.
Child Protection The product must be kept out of the sight and reach of children.
Disposal Instructions Dispose of unused or expired medicine in accordance with local requirements. It should not be disposed of via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bronax Flex found in:

A-Z Index: